Phase II trial of ponatinib in patients with bevacizumab‐refractory glioblastoma

BACKGROUND: Responses to bevacizumab in glioblastoma (GBM) are not durable. Plasma levels of basic fibroblast growth factor (bFGF) increase at the time of tumor progression. By targeting vascular endothelial growth factor receptor (VEGFR), platelet‐derived growth factor receptor, Src, and FGF recept...

Descripción completa

Detalles Bibliográficos
Autores principales: Lee, Eudocia Q., Muzikansky, Alona, Duda, Dan G., Gaffey, Sarah, Dietrich, Jorg, Nayak, Lakshmi, Chukwueke, Ugonma N., Beroukhim, Rameen, Doherty, Lisa, Laub, Caroline Kane, LaFrankie, Debra, Fontana, Brittney, Stefanik, Jennifer, Ruland, Sandra, Caruso, Victoria, Bruno, Jennifer, Ligon, Keith, Reardon, David A., Wen, Patrick Y.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2019
Materias:
Clinical Cancer Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792497/
https://www.ncbi.nlm.nih.gov/pubmed/31444999
http://dx.doi.org/10.1002/cam4.2505

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6792497/
https://www.ncbi.nlm.nih.gov/pubmed/31444999
http://dx.doi.org/10.1002/cam4.2505

Ejemplares similares